• Adam Manhi (chair)

• Emma Salib (programme manager)

• Jennifer McCaffery (lay)

• Hayley Hall (lay)

• Sonia Patton (patient)

• Trishna Bharadia (patient)

• Yanrong Jiang (clinical)

No conflicts declared by panel

Approved

• Broad agreement the lay summary was clear, well-written and easy to follow.

• Clear cohort with unmet need and limited treatment options which become less effective over time.

• Comprehensive explanation of use cases, including analyses and patient benefit.

• Clear case for why access to RWD is required, giving more representative insights than clinical trials.

• Transparent explanation of previous work with Flatiron and positive impact.

• The panel raised several comments on other aspects of the application including:
  
  

  • Patient cohort with ‘unmet need’ could have been elaborated on further (e.g. # patients; survival rates; side effects of current medications).

  • Further detail on Novartis plans for indications in metastatic prostate cancer would be appreciated.

  • More detail could have been provided on DEI (e.g. existing health inequalities; examples of Novartis’ DEI work).

  • Would have liked more information on how Novartis would engage with patients through the process, including integrating feedback and disseminating findings.